Please use this identifier to cite or link to this item:
https://scholarbank.nus.edu.sg/handle/10635/126970
DC Field | Value | |
---|---|---|
dc.title | Potential pitfall of FDG PET/CT in assessing residual masses postchemotherapy. | |
dc.contributor.author | Lu, S.J. | |
dc.contributor.author | Wong, A.S. | |
dc.contributor.author | Seet, J.E. | |
dc.contributor.author | Hao, C. | |
dc.contributor.author | Sinha, A. | |
dc.date.accessioned | 2016-09-06T09:10:27Z | |
dc.date.available | 2016-09-06T09:10:27Z | |
dc.date.issued | 2013-04 | |
dc.identifier.issn | 15360229 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/126970 | |
dc.description.abstract | A 22-year-old man with primary mediastinal choriocarcinoma and bilateral lung metastases underwent an FDG PET/CT scan after completing chemotherapy. Serum beta-human chorionic gonadotropin had normalized. PET/CT showed increased FDG uptake in the anterior mediastinal and lung lesions, suspicious for residual disease. After resection of the mediastinal and lung lesions, histopathology revealed necrosis and fibrohistiocytic reaction with no viable tumor. There was discordance between beta-human chorionic gonadotropin (negative) and FDG PET/CT (positive) findings, with PET/CT findings being false positive. Awareness of this potential pitfall of FDG PET/CT is important, and caution should be exercised when using FDG PET/CT to assess residual masses after chemotherapy. | |
dc.source | Scopus | |
dc.type | Article | |
dc.contributor.department | PATHOLOGY | |
dc.contributor.department | DIAGNOSTIC RADIOLOGY | |
dc.description.sourcetitle | Clinical nuclear medicine | |
dc.description.volume | 38 | |
dc.description.issue | 4 | |
dc.description.page | e200-204 | |
dc.identifier.isiut | NOT_IN_WOS | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.